Business
Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program
Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider and Chimeric Therapeutics (ASX: CHM, "Chimeric" or the "Company"), a leading Australian cell therapy company, today announced a 100% batch manufacturing and release success rate in support of Chimeric Therapeutics' CDH17-targeted autologous CAR-T program in Phase 1A/1B for gastrointestinal (GI) cancers, including colorectal and gastric cancer as we
About this update from Chimeric Therapeutics Limited
[{"type":"text","content":"Five-year collaboration supports consistent clinical supply for Phase 1A/1B GI cancer study","length":91,"tagName":"p","attribs":{}},{"type":"text","content":"PHILADELPHIA and MELBOURNE, Australia, April 21, 2026 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider and Chimeric Therapeutics (ASX: CHM, "Chimeric" or the "Company"), a leading Australian cell therapy company, today announced a 100% batch manufacturing and release success rate in support of Chimeric Therapeutics' CDH17-targeted autologous CAR-T program in Phase 1A/1B for gastrointestinal (GI) cancers, including colorectal and gastric cancer as well as neuroendocrine cancers.","length":623,"tagName":"p"},{"type":"image","alt":"minaris.com","displaySize":"","headline":null,"caption":"minaris.com","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":177,"url":"https://media.zenfs.com/en/prnewswire.com/37535c846dfc934a11186e39704f57a7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FFBcdqKGA77V.cxRFVJPAg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMxMg--/https://media.zenfs.com/en/prnewswire.com/37535c846dfc934a11186e39704f57a7","width":400,"height":177}},"href":"https://mma.prnewswire.com/media/2960932/Minaris_Logo_rgb__1___1_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Over the past five years of collaboration, Minaris has supported a consistent clinical manufacturing cadence of approximately one autologous batch per month, with planned expansion to two batches per month based on patient enrollment and trial requirements. Throughout this period, the program has maintained a 100% success rate in manufacturing and release.","length":358,"tagName":"p"},{"type":"text","content":"Minaris provides end-to-end GMP manufacturing and full release testing for the Phase 1A/1B clinical study. The partnership has also included process and analytical development, as well as technology transfer, to enable a seamless transition to GMP operations.","length":259,"tagName":"p"},{"type":"text","content":""This performance reflects what matters most in autologous cell therapy manufacturing: tight coordination, consistent execution, and a partner able to adapt workflows while maintaining rigor...